Shortened activated partial thromboplastin time, a hemostatic marker for hypercoagulable state during acute coronary event

被引:24
|
作者
Abdullah, Wan Zaidah [1 ]
Moufak, Shaimaa K.
Yusof, Zurkurnai
Mohamad, Mohd Sapawi
Kamarul, Im
机构
[1] Univ Sains Malaysia, Sch Med Sci, Dept Haematol, Kubang Kerian 16150, Kelantan, Malaysia
关键词
INCREASED RISK;
D O I
10.1016/j.trsl.2010.02.001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Various factors may contribute to a hypercoagulable state and acute vascular thrombosis. A prospective study was conducted involving 165 coronary heart disease (CHD) patients from the Cardiology Unit, Hospital Universiti Sains Malaysia. The purpose of this study was to investigate the relationship among factor VIII (FVIII), prothrombin time (PT), activated partial thromboplastin time (APTT), and activated protein C resistance (APC-R) state among CHD patients and to look for potential clinical applications from these laboratory findings. There were 110 cases diagnosed as acute coronary syndrome (ACS), whereas another 55 were stable coronary artery disease (SCAD) patients. PT, APTT, FVIII, and APC-R assays were performed on all subjects. There was a significant difference between the FVIII level and the APTT results (P value <0.0001). A negative relationship was found between the FVIII level and the APTT from linear regression analysis (R-2 = 10%, P value < 0.0001). For each 1% increase in the FVIII level, the APTT was reduced by 0.013 s (95% confidence interval (Cl) between -0.019 and -0.007). Interestingly, none of the SCAD patients had abnormally short APTT. Approximately 68.4% of cases with a positive APC-R assay were found to have a high FVIII level. In conclusion, the APTT test is a potential hemostatic marker for hypercoagulable state including in arterial thrombosis. (Translational Research 2010;155:315-319)
引用
收藏
页码:315 / 319
页数:5
相关论文
共 50 条
  • [41] Prolonged activated partial thromboplastin time (aPTT) during presurgical testing in 154 children.
    Rifkin, S
    Karayalcin, G
    BLOOD, 1999, 94 (10) : 236A - 236A
  • [42] Genetic Associations for Activated Partial Thromboplastin Time and Prothrombin Time, their Gene Expression Profiles, and Risk of Coronary Artery Disease
    Tang, Weihong
    Schwienbacher, Christine
    Lopez, Lorna M.
    Ben-Shlomo, Yoav
    Oudot-Mellakh, Tiphaine
    Johnson, Andrew D.
    Samani, Nilesh J.
    Basu, Saonli
    Goegele, Martin
    Davies, Gail
    Lowe, Gordon D. O.
    Tregouet, David-Alexandre
    Tan, Adrian
    Pankow, James S.
    Tenesa, Albert
    Levy, Daniel
    Volpato, Claudia B.
    Rumley, Ann
    Gow, Alan J.
    Minelli, Cosetta
    Yarnell, John W. G.
    Porteous, David J.
    Starr, John M.
    Gallacher, John
    Boerwinkle, Eric
    Visscher, Peter M.
    Pramstaller, Peter P.
    Cushman, Mary
    Emilsson, Valur
    Plump, Andrew S.
    Matijevic, Nena
    Morange, Pierre-Emmanuel
    Deary, Ian J.
    Hicks, Andrew A.
    Folsom, Aaron R.
    AMERICAN JOURNAL OF HUMAN GENETICS, 2012, 91 (01) : 152 - 162
  • [43] Plasma prothrombin time and activated partial thromboplastin time as predictors of bleeding manifestations during dengue hemorrhagic fever
    Budastra, I. N.
    Arhana, B. N. P.
    Mudita, I. B.
    PAEDIATRICA INDONESIANA, 2009, 49 (02) : 69 - 74
  • [44] Coagulation Tests as Predictive Parameters of Acute Liver Toxicity in Phalloides Syndrome: Thrombin Time and Activated Partial Thromboplastin Time
    Pereska, Z.
    Petkovska, L.
    Bozinovska, C.
    Cibisev, A.
    Petrovski, D.
    Simonovska, N.
    Babulovska, A.
    Jurukov, I
    CLINICAL TOXICOLOGY, 2011, 49 (03) : 244 - 244
  • [45] CHANGES OF ACTIVATED PARTIAL THROMBOPLASTIN TIME DURING CONSTANT INTRAVENOUS AND FIXED INTERMITTENT SUBCUTANEOUS ADMINISTRATION OF HEPARIN
    FAGRELL, B
    ARVER, S
    INTAGLIETTA, M
    TSAI, AG
    JOURNAL OF INTERNAL MEDICINE, 1989, 225 (04) : 257 - 260
  • [46] Bedside versus laboratory activated partial thromboplastin time assay during various treatments with anticoagulants RA
    Faaij
    Burggraaf, J
    Schoemaker, RC
    Cohen, AF
    THROMBOSIS AND HAEMOSTASIS, 1999, : 751 - 751
  • [47] SEQUENTIAL HOURLY ACTIVATED PARTIAL THROMBOPLASTIN TIME MONITORING DURING HEPARIN-THERAPY IN VENOUS THROMBOEMBOLISM
    FISHMAN, AJ
    MOSER, KM
    FEDULLO, PF
    CHEST, 1983, 84 (03) : 329 - 329
  • [48] Activated Partial Thromboplastin Time or Prothrombin Time Prolongation During Rivaroxaban Administration: Clinical Risk Factors and Outcomes Analysis
    Yuan, Yao
    Li, Xinyu
    Qiu, Feng
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2023, 29
  • [49] Heparin dose adjustment required to maintain goal-activated partial thromboplastin time during therapeutic hypothermia
    Fevold, Ryan T.
    Leung, Yuk Ting Lydia
    Garofoli, Adrian C.
    White, Roger D.
    Barsness, Gregory W.
    Dierkhising, Ross A.
    Ou, Narith N.
    JOURNAL OF CRITICAL CARE, 2015, 30 (03) : 574 - 578
  • [50] Activated Partial Thromboplastin Time Correlates with Methoxyhydroxyphenylglycol in Acute Myocardial Infarction Patients: Therapeutic Implications for Patients at Cardiovascular Risk
    Pinelli, Arnaldo
    Trivulzio, Silvio
    Rossoni, Giuseppe
    IN VIVO, 2014, 28 (01): : 99 - 104